financial stipend was paid by Nature Biotechnology

October 13th, 2008

financial stipend was paid by Nature Biotechnology to Robert Paull for research on, and writing of, this article. The current commercial path for nanotechnology ventures mirrors the early evolution of the biotechnology industry, allowing similar strategies toward both technology commercialization and investment opportunities.TopContents Editorial News Feature Features Perspectives Reviews Careers Feedback Nature Biotechnology21, 2003 doi10. 1038nbt10031144 Investing in nanotechnologyRobert Paull, Josh Wolfe, Peter Hbert&Michael Sinkula The authors are at Lux Capital, Park Avenue, 24th Floor, New York, NY, USA Lux Capital is venture capital firm focused on making earlystage investments in nanotechnology. rpaullluxcapital. com. rpaullluxcapital.

Lux Capital is venture capital firm focused on making earlystage

NextTable of contentsFull textDownload PDFSend to friendSave this linkFigures & TablesExport citationnature jobs Petrochemical technician Physicschemical engineer KSR PLEASANTON, CA, USA Newton International Fellowships Royal Society, British Academy, Royal Society of Engineering United Kingdom More science jobs Search buyers guide ADVERTISEMENTFeature Contents Editorial News Feature Features Perspectives Reviews Careers Feedback Nature Biotechnology21, 2003 doi10. 1038nbt10031144 Investing in nanotechnologyRobert Paull, Josh Wolfe, Peter Hbert&Michael Sinkula The authors are at Lux Capital, Park Avenue, 24th Floor, New York, NY, USA financial stipend was paid by Nature Biotechnology to Robert Paull for research on, and writing of, this article.

Lux Capital is venture capital firm focused on making earlystage investments in nanotechnology. financial stipend was paid by Nature Biotechnology to Robert Paull for research on, and writing of, this article. The current commercial path for nanotechnology ventures mirrors the early evolution of the biotechnology industry, allowing similar strategies toward both technology commercialization and investment opportunities.TopContents Editorial News Feature Features Perspectives Reviews Careers Feedback Nature Biotechnology21, 2003 doi10. 1038nbt10031144 Investing in nanotechnologyRobert Paull, Josh Wolfe, Peter Hbert&Michael Sinkula The authors are at Lux Capital, Park Avenue, 24th Floor, New York, NY, USA rpaullluxcapital.

Journal homeAdvance online publication Current issueArchive Press to authors Online submissionPermissionsFor refereesFree online issueContact the this siteFor librariansNPG Reviews Drug DiscoveryNatureNature MedicineNature Genetics Nature Reviews Genetics Nature Methods Nature Chemical Biology newsnature. com Clinical Pharmacology & Therapeutics Nature Conferences NPG Subject areas Biotechnology Cancer Chemistry ClinicalMedicine Dentistry Development Drug Discovery Earth Sciences Evolution & Ecology Genetics Immunology Materials Science Medical Research Microbiology Molecular CellBiology Neuroscience Pharmacology Physics Browseall publications Feature Contents Editorial News Feature Features Perspectives Reviews Careers Feedback Nature Biotechnology21, 2003 doi10.